European Cyberknife Center Munich Grosshadern, Max-Lebsche-Platz 31, 81377 Munich, Germany.
Technol Cancer Res Treat. 2012 Feb;11(1):27-34. doi: 10.7785/tcrt.2012.500231.
Purpose of this study is to analyze local control, clinical symptoms and toxicity after image-guided radiosurgery of spinal meningiomas and schwannomas. Standard treatment of benign spinal lesions is microsurgical resection. While a few publications have reported about radiosurgery for benign spinal lesions, this is the first study analyzing the outcome of robotic radiosurgery for benign spinal tumors, treated exclusively with a non-invasive, fiducial free, single-fraction setup. Thirty-six patients with spinal meningiomas or schwannomas were treated, utilizing a robotic radiosurgery system (CyberKnife®, Accuray Inc. Sunnyvale CA), and were followed prospectively. Medical history, histology, clinical symptoms and radiographic outcome were recorded. Thirty-nine spinal lesions were treated because of tumor recurrence, remnants after microsurgery, multiple lesions, or rejection of open surgery. Median age was 45 years (range 18-80 years). Median target volume was 3.4 cm(3) (range 0.2-43.4 cm(3)). Histology revealed 28 schwannomas and 11 meningiomas (WHO grade I). All spinal levels were affected. Median prescription dose was 14 Gray (95% C.I. 13.4-14 Gy) to the 70% isodose. After a median follow-up of 18 months (range 6-50 months) no local tumor progression was detected. 20 lesions (51%) remained stable, 19 tumors (49%) decreased in size. One patient with schwannomatosis was treated repeatedly for three new tumor locations. Pain was the initial symptom in 16 of 25 schwannoma patients, and in 3 of 11 patients with meningiomas. Pain levels decreased in 8/19 patients. All but one patient with motor deficits remained clinically stable. No myelopathic signs where found. Single-session radiosurgery for benign spinal tumors in selected patients has proven to inhibit tumor progression within the observed period without signs of early toxicity. Radiosurgery offers an additional treatment option, if microsurgery is not feasible in cases of tumor recurrence, post-resection remnants, multiple lesions, or medical comorbidity.
本研究旨在分析脊柱脑膜瘤和神经鞘瘤经影像引导放射外科治疗后的局部控制、临床症状和毒性。良性脊柱病变的标准治疗是显微切除术。虽然有一些出版物报道了良性脊柱病变的放射外科治疗,但这是第一项分析机器人放射外科治疗良性脊柱肿瘤的结果的研究,这些肿瘤仅采用非侵入性、无基准、单次分割的设置进行治疗。36 名患有脊柱脑膜瘤或神经鞘瘤的患者接受了治疗,使用机器人放射外科系统(CyberKnife®,Accuray Inc. 加利福尼亚州森尼韦尔),并进行了前瞻性随访。记录了病史、组织学、临床症状和影像学结果。由于肿瘤复发、显微手术后残留、多发病变或拒绝开放手术,共治疗了 39 个脊柱病变。中位年龄为 45 岁(范围 18-80 岁)。中位靶体积为 3.4cm³(范围 0.2-43.4cm³)。组织学显示 28 例神经鞘瘤和 11 例脑膜瘤(WHO 分级 I)。所有脊柱水平均受影响。中位处方剂量为 14Gy(95%置信区间 13.4-14Gy)至 70%等剂量线。中位随访时间为 18 个月(范围 6-50 个月),未发现局部肿瘤进展。20 个病变(51%)保持稳定,19 个肿瘤(49%)缩小。一名神经鞘瘤病患者因三个新的肿瘤部位而反复接受治疗。25 例神经鞘瘤患者中有 16 例最初表现为疼痛,11 例脑膜瘤患者中有 3 例。19 例患者中有 8 例疼痛减轻。除 1 例运动功能障碍患者外,所有患者均保持临床稳定。没有发现脊髓病迹象。在选定的患者中,单次分割放射外科治疗良性脊柱肿瘤在观察期内已被证明可抑制肿瘤进展,且无早期毒性迹象。如果肿瘤复发、术后残留、多发病变或合并症使显微切除术不可行,放射外科可作为另一种治疗选择。